stockportfolio.pro
Stocks / AMRX vs CAI
AMRX vs CAI
Amneal Pharmaceuticals, Inc. and Caris Life Sciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Amneal Pharmaceuticals, Inc. (AMRX) | Caris Life Sciences, Inc. (CAI) | |
|---|---|---|
| Market cap | $4.9B | $5.0B |
| Revenue (latest FY) | $3.02B | $812.03M |
| Net income (latest FY) | $72.06M | $-68.09M |
| Revenue growth (5y CAGR) | 8.7% | 46.5% |
| Net margin | 2.4% | -8.4% |
| Return on equity | -101.8% | -11.8% |
| P/E ratio | 41.3 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 0 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AMRX — free Open CAI — freeFrequently asked questions
Which is bigger, AMRX or CAI?
Caris Life Sciences, Inc. is larger by market capitalization — $5.0B versus $4.9B.
Which grows faster, AMRX or CAI?
Over the last five fiscal years, Caris Life Sciences, Inc. grew revenue faster — 46.5%/yr versus 8.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.